SBIR Phase I: Microbe and Cell Assay (MICA) Device for Measuring Bacteria Antibiotic Susceptibility

SBIR 第一阶段：用于测量细菌抗生素敏感性的微生物和细胞测定 (MICA) 装置

• 批准号: 0740008
• 负责人: John Stencel
• 金额: --
• 依托单位: Tribo Flow Separations, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0740008&HistoricalAwards=false
• 关键词: SBIR; Phase; Microbe; Cell; Assay

This Small Business Innovative Research Phase I project demonstrates the feasibility of a device for rapidly determining the susceptibility of infectious bacteria to antibiotic treatments. Whereas standard susceptibility tests take between 24-96 hours, this device promises to provide assessments in less than two hours without the use of specialized reaction surfaces. To demonstrate feasibility, the real-time activity of bacteria will be monitored during growth in nutrient broths before and after exposure to dosages of simulated antibiotics. Signatures of two distinct bacteria will be followed, minimum measurable concentrations determined, integrative concepts and partnerships for this instrumentation established, and design of a prototype completed.The broader impacts of this research are improved speed and accuracy for diagnosing and treating patients having bacterial infections, decreased costs for patient care at hospitals, emergency departments, physician offices/satellite facilities and point-of-care providers, and heightened automation and ease of operation for a front-line approach that improves health givers' abilities to treat infectious disease and save lives. Furthermore, successful implementation would point to other potential applications in medical, biopharmaceutical and clinical settings.

这个小型企业创新研究I期项目证明了快速确定感染性细菌对抗生素治疗敏感性的设备的可行性。虽然标准的敏感性测试需要24-96小时，但该设备承诺在不到两小时内提供评估，而无需使用专门的反应表面。为了证明可行性，在暴露于模拟抗生素剂量之前和之后，将在营养肉汤中生长期间监测细菌的实时活性。两种不同细菌的特征将被跟踪，确定最低可测量浓度，建立这种仪器的综合概念和伙伴关系，并完成原型的设计。这项研究的更广泛影响是提高诊断和治疗细菌感染患者的速度和准确性，降低医院，急诊科，医疗保健服务将包括医生办公室/卫星设施和护理点提供者，提高自动化程度，简化一线方法的操作，提高保健人员治疗传染病和拯救生命的能力。此外，成功的实施将指向医疗、生物制药和临床环境中的其他潜在应用。